HC Wainwright Analysts Decrease Earnings Estimates for ADAP

Adaptimmune Therapeutics plc (NASDAQ:ADAP) – HC Wainwright cut their FY2028 earnings per share estimates for Adaptimmune Therapeutics in a research note issued to investors on Wednesday, May 14th. HC Wainwright analyst A. He now anticipates that the biotechnology company will post earnings per share of $0.02 for the year, down from their prior forecast of $0.06. HC Wainwright has a “Buy” rating and a $3.00 price target on the stock. The consensus estimate for Adaptimmune Therapeutics’ current full-year earnings is ($0.14) per share.

Other equities research analysts also recently issued research reports about the company. Jones Trading downgraded Adaptimmune Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 11th. Wells Fargo & Company lowered their price target on Adaptimmune Therapeutics from $1.50 to $1.00 and set an “equal weight” rating for the company in a report on Wednesday. StockNews.com initiated coverage on Adaptimmune Therapeutics in a report on Friday. They issued a “buy” rating for the company. Scotiabank lowered their price target on Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating for the company in a report on Friday, March 21st. Finally, Barclays lowered their price target on Adaptimmune Therapeutics from $1.00 to $0.46 and set an “underweight” rating for the company in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, Adaptimmune Therapeutics has an average rating of “Moderate Buy” and an average price target of $1.52.

Adaptimmune Therapeutics Price Performance

Shares of ADAP stock opened at $0.26 on Thursday. Adaptimmune Therapeutics has a 1-year low of $0.20 and a 1-year high of $1.48. The stock’s 50-day moving average is $0.29 and its 200 day moving average is $0.51. The company has a market cap of $68.09 million, a P/E ratio of -1.20 and a beta of 2.86. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.82.

Adaptimmune Therapeutics (NASDAQ:ADAP) last issued its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.18) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.18). Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%. The company had revenue of $7.29 million for the quarter, compared to the consensus estimate of $6.55 million.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Two Sigma Investments LP raised its stake in shares of Adaptimmune Therapeutics by 33.5% in the fourth quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 19,146 shares during the last quarter. Virtu Financial LLC raised its stake in shares of Adaptimmune Therapeutics by 21.5% in the fourth quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company’s stock worth $66,000 after purchasing an additional 21,688 shares during the last quarter. Invesco Ltd. raised its stake in shares of Adaptimmune Therapeutics by 82.0% in the fourth quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 28,526 shares during the last quarter. Rock Springs Capital Management LP raised its stake in shares of Adaptimmune Therapeutics by 2.4% in the fourth quarter. Rock Springs Capital Management LP now owns 2,483,468 shares of the biotechnology company’s stock worth $1,338,000 after purchasing an additional 58,000 shares during the last quarter. Finally, Two Sigma Advisers LP raised its stake in shares of Adaptimmune Therapeutics by 492.0% in the fourth quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 58,787 shares during the last quarter. 31.37% of the stock is currently owned by hedge funds and other institutional investors.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.